Assessing Liver Function in Patients with HCC : Episode 8
Opinion
Video
Rivoceranib plus Camrelizumab for First-Line Treatment of HCC: Data from CARES-310
Author(s):
Rachna Shroff, MD, MS, FASCO, shares data from the CARES-310 study showing improved progression-free and overall survival in patients with hepatocellular carcinoma treated with camrelizumab and rivoceranib compared to sorafenib, regardless of liver function.
EP: 1.Risk Factors of Hepatocellular Carcinoma (HCC)
EP: 2.Importance of Assessing Liver Function in HCC
EP: 3.Assessing Liver Function in Patients With HCC: The ALBI Score
EP: 4.Assessing Liver Function in Patients With HCC: The Child-Pugh Score
EP: 5.Assessing Liver Function in Patients With HCC: The MELD Score
EP: 6.Updates in First-Line Systemic Therapy for Patients With HCC
EP: 7.Key Outcomes Data in Patients With HCC Based on Liver Function
Now Viewing
EP: 8.Rivoceranib plus Camrelizumab for First-Line Treatment of HCC: Data from CARES-310
EP: 9.The Future of Liver Function Assessments in HCC
Related Videos
Related Content
